Phase 3 Readout
BCTX: Phase 3 Topline: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice
June 1, 2028 · bria-imt. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2028
- Company
- BriaCell Therapeutics Corp. (BCTX)
- Drug
- bria-imt
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice
- Drug
- bria-imt
- Indication
- Breast Cancer; Metastatic Breast Cancer; Breast Cancer Metastatic